Prodrugs of the Cytostatic CC‐1065 That Can Be Activated in a Tumor‐Selective Manner

Abstract

The O-glycosides 1 of the seco-CI derivative 2, which is the seco form of the simplified pharmacophoric group of the potent cytotoxic antibiotic CC-1065, show only very low toxicity. In tumor-selective cancer therapy they can be used in conjunction with conjugates of glycohydrolases and monoclonal antibodies that bind at tumor-associated antigens. The glycohydrolases cleave the prodrugs 1 and release the cytotoxic components 2.